A negative trial for vasoactive intestinal peptide in COVID-19-associated acute hypoxaemic respiratory failure
- PMID: 37348523
- PMCID: PMC10278994
- DOI: 10.1016/S2213-2600(23)00218-7
A negative trial for vasoactive intestinal peptide in COVID-19-associated acute hypoxaemic respiratory failure
Conflict of interest statement
ASS consults for Cellenkos and SaNOtize in relation to therapies for COVID-19. WLL is listed as a co-inventor on the use of vasculotide for influenza-induced lung injury and on the use of ultrasound and microbubbles to treat acute respiratory distress syndrome.
Comment on
-
Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial.Lancet Respir Med. 2023 Sep;11(9):791-803. doi: 10.1016/S2213-2600(23)00147-9. Epub 2023 Jun 19. Lancet Respir Med. 2023. PMID: 37348524 Free PMC article. Clinical Trial.
Similar articles
-
Outcomes in mechanically ventilated patients with hypoxaemic respiratory failure caused by COVID-19.Br J Anaesth. 2020 Dec;125(6):e480-e483. doi: 10.1016/j.bja.2020.08.047. Epub 2020 Sep 3. Br J Anaesth. 2020. PMID: 32962855 Free PMC article. No abstract available.
-
Noninvasive ventilation for COVID-19-associated acute hypoxaemic respiratory failure: experience from a single centre.Br J Anaesth. 2020 Oct;125(4):e368-e371. doi: 10.1016/j.bja.2020.07.008. Epub 2020 Jul 21. Br J Anaesth. 2020. PMID: 32811662 Free PMC article. No abstract available.
-
Rethinking the efficacy of awake prone positioning in COVID-19-related acute hypoxaemic respiratory failure.Lancet Respir Med. 2022 Jun;10(6):e53. doi: 10.1016/S2213-2600(22)00164-3. Lancet Respir Med. 2022. PMID: 35659008 Free PMC article. No abstract available.
-
Non-invasive support for the hypoxaemic patient.Br J Hosp Med (Lond). 2023 Jan 2;84(1):1-10. doi: 10.12968/hmed.2022.0420. Epub 2023 Jan 24. Br J Hosp Med (Lond). 2023. PMID: 36708347 Review.
-
Awake prone positioning for non-intubated patients with COVID-19-related acute hypoxaemic respiratory failure: a systematic review and meta-analysis.Lancet Respir Med. 2022 Jun;10(6):573-583. doi: 10.1016/S2213-2600(22)00043-1. Epub 2022 Mar 16. Lancet Respir Med. 2022. PMID: 35305308 Free PMC article.
References
-
- Brown SM, Barkauskas CE, Grund B, et al. Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial. Lancet Respir Med. 2023 doi: 10.1016/S2213-2600(23)00147-9. published online June 19. - DOI - PMC - PubMed
-
- Grimm MC, Newman R, Hassim Z, et al. Cutting edge: vasoactive intestinal peptide acts as a potent suppressor of inflammation in vivo by trans-deactivating chemokine receptors. J Immunol. 2003;171:4990–4994. - PubMed
-
- Delgado M, Ganea D. Inhibition of IFN-gamma-induced janus kinase-1-STAT1 activation in macrophages by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. J Immunol. 2000;165:3051–3057. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical